Open AccessRoles of N 6 ‐methyladenosine (m 6 A) RNA modifications in urological cancers
Author(s) -
Wang Xiao,
Xie Haiyun,
Ying Yufan,
Chen Danni,
Li Jiangfeng
Publication year - 2020
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.15750
Subject(s) - rna , epigenetics , methyltransferase , demethylase , biology , non coding rna , chromatin , histone , computational biology , methylation , n6 methyladenosine , dna methylation , genetics , dna , cancer research , gene , gene expression
Epigenetics has long been a hot topic in the field of scientific research. The scope of epigenetics usually includes chromatin remodelling, DNA methylation, histone modifications, non‐coding RNAs and RNA modifications. In recent years, RNA modifications have emerged as important regulators in a variety of physiological processes and in disease progression, especially in human cancers. Among the various RNA modifications, m 6 A is the most common. The function of m 6 A modifications is mainly regulated by 3 types of proteins: m 6 A methyltransferases (writers), m 6 A demethylases (erasers) and m 6 A‐binding proteins (readers). In this review, we focus on RNA m 6 A modification and its relationship with urological cancers, particularly focusing on its roles and potential clinical applications.